Table 4:
Rate of Select Adverse Events (%) in Key mRCC Immune Checkpoint Inhibitor Trials
| Nivolumab13 | Pembrolizumab14 | Nivolumab + ipilimumab17 | Pembrolizumab + axitinib28 | Avelumab + axitinib26 | Atezolizumab + bevacizumab20 | |
|---|---|---|---|---|---|---|
| Trial | CheckMate-025 | KEYNOTE-427 | CheckMate-214 | KEYNOTE-426 | JAVELIN RENAL 101 | IMmotion-151 |
| Fatigue | 2.5% | -- | 4% | 2.8% | 3.5% | 4.3% |
| Rash | <1% | 1.8% | 1% | 0.2% | 0.5% | Not reported |
| Palmar-plantar erysthodysesthesia | -- | -- | -- | 5.1% | 5.8% | -- |
| Hypertension | -- | -- | <1% | 22.1% | 25.6% | 13.9% |
| Proteinuria | -- | -- | -- | 2.8% | -- | <3% |
| Diarrhea | 1.2% | 3.6% | 4% | 9.1% | 6.7% | 22% |
| Transaminitis | -- | 1.8% | -- | See below | See below | Not reported |
| AST elevation | -- | Not reported | -- | 13.3% | 6% | Not reported |
| ALT elevation | -- | Not reported | -- | 7% | 3.9% | Not reported |
| Colitis | -- | 2.7% | -- | -- | -- | -- |
| Anemia | 1.8% | -- | <1% | 0.7% | 1.6% | -- |
| Thyroid dysfunction | -- | -- | <1% | 0.2 | 0.2 | Not reported |
| Pneumonitis | 1.5% | 0.9% | -- | 0.2% | -- | -- |